Bayer Stock Holds Its Breath as EMA and Supreme Court Calendars Collide
13.06.2026 - 05:04:20 | boerse-global.de
Bayer is bracing for a fortnight of high-stakes decisions that could reshape its outlook on two fronts. The European Medicines Agency has validated the marketing application for the stroke drug Asundexian, kicking off a formal review in Europe, while the U.S. Supreme Court is set to deliver an opinion on a key glyphosate case on June 18. The convergence of regulatory and judicial events has left investors in a wait-and-see posture, with the stock trading at €36.15—roughly 28% below its 52-week high of €49.93 and just above its long-term moving average of €35.99.
The EMA validation of Asundexian marks the first filing of a Factor XIa inhibitor in Europe. The drug, backed by data from the Phase III OCEANIC-STROKE trial, targets secondary prevention of ischemic stroke with a reportedly low bleeding risk. After an early setback in atrial fibrillation patients in 2023, Bayer repositioned the asset and is now pursuing simultaneous approvals in three markets: China and the U.S. have already granted Priority Review. The market opportunity is significant—stroke is the second-leading cause of death in Europe, where about 10 million people live with its consequences.
On the legal front, the imminent Supreme Court decision in the "Durnell" glyphosate case carries the heaviest weight for the stock. Analyst Sebastian Bray of Berenberg, who raised his price target on Bayer from €40.00 to €40.50 while keeping a "Hold" rating, puts the odds of a favorable ruling at 60%—barely better than a coin toss. He cites improved pharma profitability and favorable currency effects for the target adjustment, but remains cautious on the glyphosate overhang, noting many open outcomes even if a settlement emerges.
Should investors sell immediately? Or is it worth buying Bayer?
The financial drag from litigation is already measurable. In the first quarter of 2026, net cash outflows topped €2 billion, mostly tied to PCB and glyphosate claims. That burden has driven the dividend down to just €0.11 per share for fiscal 2025. The company’s free cash flow swung to minus €2.3 billion in the same period, even as overall revenue grew on a currency-adjusted basis to €13.4 billion and operating profit rose 9%.
Away from the courtroom and the lab, Bayer is reshuffling its management ranks. The consumer health division is getting four new top managers: Samantha Avivi for global marketing, Analia de la Fuente for data analytics, and David Tomasi for worldwide sales. In pharma, Dr. Jost Reinhard will take over the radiology unit on August 1, reporting directly to pharma head Stefan Oelrich. The moves signal an internal focus on operational efficiency as the group navigates external volatility.
Technically, the stock has been consolidating near its 50-day moving average, with a modest intraday gain breaking the short-term drift. But the next decisive move hinges on the Supreme Court's opinion day. A ruling in Bayer's favor would remove the largest single uncertainty hanging over the shares, potentially triggering a relief rally. An adverse outcome, by contrast, would intensify pressure on an already defensive shareholder base.
For now, the Asundexian review offers a separate, longer-term catalyst that could diversify Bayer's pipeline narrative away from its litigation woes. But with the Supreme Court verdict days away, the immediate direction of the stock will be decided in Washington, not Frankfurt.
Ad
Bayer Stock: New Analysis - 13 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
